Why Did Virax Biolabs Stock Triple In One Session?

Virax Biolabs Group Limited (NASDAQ:VRAX) stock is up during Thursday’s premarket session, as the company has signed a multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line, which is aimed at immune profiling.

The agreement opens access to multiple Southeast Asian markets, potentially driving significant revenue growth for the company as it expands its commercial footprint.

Virax Biolabs is developing in vitro diagnostic technologies for viral and immune-mediated diseases, with an initial strategic focus on post-acute infection syndromes, including Long COVID, and related areas of chronic immune dysfunction.

VRAX Stock Jumps On Fosun Diagnostics Supply Deal

ImmuneSelect is Virax’s commercially available research-use-only (RUO) immune profiling product line and is distinct from ViraxImmune, the company’s in-development diagnostic platform currently progressing through clinical and regulatory development.

The exclusive agreement covers six Southeast Asian markets, including Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia, and establishes a framework for immediate product supply under purchase orders.

The partnership is expected to support near-term revenue opportunities and regional commercial expansion, particularly focusing on tuberculosis-related research applications in Thailand.

Recently, Virax Biolabs concluded a share consolidation at a 1-for-25 ratio.

In May, Virax Biolabs shared positive early pilot performance data for its blood-based test, ViraxImmune, for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome, and related post-acute infection syndromes.

In the pilot dataset, ViraxImmune demonstrated measurable separation between PAIS patients and healthy controls, achieving 88% specificity and 92% positive predictive value — early performance metrics that Virax believes support continued development and advancement into larger clinical validation.

VRAX Price Action: Virax Biolabs Group shares were up 228.13% at $10.43 at the time of publication on Thursday, according to Benzinga Pro data.

Image via Shutterstock